• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Topics » Addiction Treatment » Files

Addiction Treatment

Pain Management for Patients With Opioid Use Disorder

February 28, 2024

Pain and opioid use disorder (OUD) are tightly intertwined and highly comorbid. OUD arises in some patients who receive opioids as treatment for acute or chronic pain. Opioid misuse can provide potent analgesia, and opioid withdrawal can exacerbate pain. Treating chronic pain in patients with OUD is a challenge, but keeping the following principles in mind can be helpful.

Overview of Treatment Options for Opioid Use Disorder

February 28, 2024

As treatment options for patients with opioid use disorder (OUD) expand, it’s important to have a handy overview available to guide your conversations with patients. In this fact sheet, we cover the most evidence-based treatments and provide guidance for how to choose among them.

Opioid Use Disorder Psychosocial Approaches

February 28, 2024

Research shows that effective opioid use disorder (OUD) treatment must include a medication such as buprenorphine, methadone, or injectable naltrexone as its main component (Amato L et al, Cochrane Database Syst Rev 2011;(10):CD004147). Nonetheless, psychosocial approaches can be valuable adjuncts to medications for many patients. In this fact sheet, we provide an overview of psychosocial options to consider when working with patients with OUD. Some of these treatments can be delivered by psychiatrists, while others may require referral to specialized providers. Having this information on hand is especially useful when a patient is not responding to standard treatments alone.

How to Choose the Right Medications for Opioid Use Disorder

February 28, 2024

The purpose of this fact sheet is not to provide details on pharmacology or the use of these medications, but rather to help you decide which might be best for a given patient. For more detailed information on each agent, see the appropriate medication fact sheet.

NALTREXONE ReVia Vivitrol Fact Sheet for Patients

February 28, 2024

Naltrexone is used in the treatment of alcohol and opioid use disorder.

LOFEXIDINE Lucemyra Fact Sheet

February 28, 2024

Lofexidine is an alpha-2 agonist (similar to clonidine and guanfacine) that is used to reduce the intensity of opioid withdrawal symptoms. It effectively blunts some of the most distressing symptoms such as anxiety and tachycardia. It is generally not effective for pain symptoms such as generalized achiness and headache, so it should be used with an analgesic like ibuprofen or acetaminophen. Data indicate that lofexidine is similarly effective to clonidine for management of opioid withdrawal but with a marginally better side effect profile (Kuszmaul AK et al, J Am Pharm Assoc 2020;60(1):145–152). However, given its much higher price tag, we recommend you stick to clonidine.

NALMEFENE Opvee Fact Sheet

February 28, 2024

Nalmefene is an opioid antagonist that has high affinity for opioid receptors and is more potent and longer acting than naloxone. Whether we need this or the newer nasal spray version remains up for debate. Nalmefene is likely not required for most patients; stick with naloxone (now available over the counter) for opioid overdose.

BUPRENORPHINE MONOTHERAPY Subutex and others Fact Sheet G

February 28, 2024

Buprenorphine (Subutex, available now only as generic) is the active ingredient in Suboxone (buprenorphine/ naloxone) and is responsible for the effectiveness of the combination medication in opioid use disorder (OUD). In the past, buprenorphine alone was preferred for the initial (induction) phase of treatment, while Suboxone was preferred for maintenance treatment (unsupervised administration). Currently, the combination is favored for both induction and maintenance as it, at least theoretically, decreases misuse and diversion.

How to Manage and Taper Buprenorphine

February 28, 2024

After you have initiated buprenorphine, see patients weekly at first to make sure the dose is right. Increase the dose if they are experiencing cravings—the maximum dose is typically 24 mg daily. Doses can be split if patients are having withdrawal symptoms between doses. Multiple doses per day can be helpful for patients with chronic pain. For most patients, the optimal dose will be 16–24 mg daily. Eventually you can see patients monthly.

NALMEFENE Opvee Fact Sheet for Patients

February 28, 2024

Nalmefene is used to reverse opioid overdose in emergency situations.

Previous 1 2 3 4 5 6 7 8 9 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.